This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holkova, B. Articles by Chanan-Khan, A. Search for Related Content PubMed PubMed Citation Articles by Holkova, B. Articles by Chanan-Khan, A. Social Bookmarking                            What's this?

Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy

From the Divisions of Hematology and Oncology, Department of Medicine, Division of Biostatistics, Department of Environmental Medicine, and Department of Pathology, Bellevue Hospital Center, New York University School of Medicine, New York; and Division of Lymphoma and Bone Marrow Transplantation, Roswell Park Cancer Institute, Buffalo, NY.

Address reprint requests to Ken Takeshita, MD, Division of Hematology, New York University School of Medicine, 550 First Ave, New York, NY 10016; email: kenichi.takeshita{at}nyu.edu

PURPOSE: Kaposi’s sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.

PATIENTS AND METHODS: A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.

RESULTS: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P = .0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P < .0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69).

CONCLUSION: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Thomas, J. M. Boname, S. Field, S. Nejentsev, M. Salio, V. Cerundolo, M. Wills, and P. J. Lehner Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity PNAS, February 5, 2008; 105(5): 1656 - 1661. [Abstract] [Full Text] [PDF]

				M. C. B. Godoy, H. Rouse, J. A. Brown, P. Phillips, D. M. Forrest, and N. L. Muller Imaging Features of Pulmonary Kaposi Sarcoma Associated Immune Reconstitution Syndrome Am. J. Roentgenol., October 1, 2007; 189(4): 956 - 965. [Abstract] [Full Text] [PDF]

				J. Stebbing, D. Mazhar, R. Lewis, C. Palmieri, E. Hatzimichael, M. Nelson, B. Gazzard, and M. Bower The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma Ann. Onc., March 1, 2006; 17(3): 503 - 506. [Abstract] [Full Text] [PDF]

				H. Masur Management of Patients with HIV in the Intensive Care Unit. Proceedings of the ATS, January 1, 2006; 3(1): 96 - 102. [Abstract] [Full Text] [PDF]

				S. E. Krown Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma: Implications for the Design of Therapeutic Trials in Patients With Advanced, Symptomatic Kaposi's Sarcoma J. Clin. Oncol., February 1, 2004; 22(3): 399 - 402. [Full Text] [PDF]

				G. Nasti, R. Talamini, A. Antinori, F. Martellotta, G. Jacchetti, F. Chiodo, G. Ballardini, L. Stoppini, G. Di Perri, M. Mena, et al. AIDS-Related Kaposi's Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals J. Clin. Oncol., August 1, 2003; 21(15): 2876 - 2882. [Abstract] [Full Text] [PDF]

				D. M. Aboulafia, D. Norris, D. Henry, R. J. Grossman, J. Thommes, D. Bundow, R. C. Yocum, and V. Stevens 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma: Results of a Phase 2 Multicenter Clinical Trial Arch Dermatol, February 1, 2003; 139(2): 178 - 186. [Abstract] [Full Text] [PDF]